Last reviewed · How we verify
NCT05165901
Clinical Effect of LG Medipain for Managing Chronic Pain Disorders
NA trial testing Scrambler Therapy in Neuropathic Pain in 90 participants. Currently enrolling.
15 January 2025
Quick facts
| Lead sponsor | Jeeyoun Moon |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 3 January 2022 |
| Primary completion | 15 January 2025 |
| Estimated completion | 15 January 2025 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Scrambler Therapy
Conditions studied
- Neuropathic Pain — all drugs for Neuropathic Pain →
- Pain — all drugs for Pain →
- Refractory Pain — all drugs for Refractory Pain →
- Chronic Pain — all drugs for Chronic Pain →
Sponsor
Jeeyoun Moon — full company profile →
Who can join
19 and older, any sex, with Neuropathic Pain or Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Scrambler Therapy is a type of non-invasive neuromodulation. According to the researches that studied the effects of the existing Scrambler therapy, 10 times of Scrambler Therapy showed a significant pain relief lasting for more than 1-3 months in various pain disorders such as post-herpetic neuralgia, cancer-related neuropathic pain, and mixed pain. No treatment-related side effects have been reported in Scrambler therapy conducted in previous studies. The most inconvenient thing about Scrambler Therapy is that it has to be treated more than 10 times during specific period, so frequent visits to the hospital for treatment linked to the higher burden for the patient's cost and even those are not fully covered by the government's insurance. To reduce this discomfort and expand the range of treatment in the era of Corona of untact treatment, LG Electronics devised a home self-scrambler treatment device for pain patients. The LG Medipain device has the same treatment function as the existing hospital Scrambler treatment device, but there has been no study on its efficacy and safety. Therefore, the investigators want to conduct this research and find out about the safety and equal efficiency of the LG Medipain Therapy. In this study, it is expected that pain relief and improvement of quality of life can be obtained for patients with various types of chronic pain through self-application of LG Medipain device.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05165901
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Scrambler Therapy
Trials testing the same drug.
- NCT06914557 — Scrambler Therapy With Duloxetine-based Usual Care vs Duloxetine-based Usual Care for Chemotherapy-induced Peripheral Ne · Phase 2 · recruiting
- NCT07174609 — Scrambler Therapy in Chronic Pancreatitis · NA · recruiting
Other recruiting trials for Neuropathic Pain
Currently open trials in the same condition.
- NCT07493213 — USG-Guided Shoulder Injections in Frozen Shoulder · NA · recruiting
- NCT07493226 — Efficacy of Chemically Distinct Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Pain Phenotypes in Adhesive Capsulitis · NA · recruiting
- NCT06398847 — Virtual Reality (VR) Self-Hypnosis Software · NA · recruiting
- NCT07487610 — Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older · recruiting
- NCT07436806 — SPS Block vs. Surgical Intercostal Block for Chronic Pain After Thoracoscopic Surgery · NA · recruiting
Other Jeeyoun Moon trials
Trials by the same sponsor.
- NCT06204952 — Effectiveness of Joins® for Managing Lumbar Facetogenic Pain · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05165901 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jeeyoun Moon
- Last refreshed: 29 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05165901.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing